Management of Epilepsy in People with Learning Disabilities

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 219-229

  Brodtkorb, Eylert ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiepileptic drug treatment; Comprehensive epilepsy service; Concomitant psychopharmacological treatment; Epilepsy management in people with learning disabilities; Rufinamide modulating sodium channel activity; Topiramate potent broad spectrum drug; Vagus nerve stimulation

Indexed keywords

EID: 84865150266     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch17     Document Type: Chapter

References (63)

1. Forsgren L. Prevalence of epilepsy in adults in Northern Sweden. Epilepsia 1992; 33: 450-458.
2. Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev 2007: CD005399.
3. Forsgren L, Edvinsson, S-O, Blomquist HK, et al. Epilepsy in a population of mentally retarded children and adults. Epilepsy Res 1990; 6: 234-248.
4. Besag FM. Cognitive and behavioral outcomes of epileptic syndromes: implications for education and clinical practice. Epilepsia 2006; 47(Suppl. 2): 119-125.
5. Alvarez N. Barbiturates in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42(Suppl. 1): 16-23.
6. Iivanainen M. Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42(Suppl. 1): 24-31.
7. Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol 2006; 48: 394-398.
8. Wheless JW, Clarke DF, Arzimanoglou A, et al. (2007) Treatment of pediatric epilepsy: European expert opinion. Epileptic Disord 9, 353-412.
9. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118: 281-290.
10. Kelly K, Stephen LJ, Brodie MJ. Pharmacological outcomes in people with mental retardation and epilepsy. Epilepsy Behav 2004; 5: 67-71.
11. Huber B, Seidel M. Update on treatment of epilepsy in people with intellectual disabilities. Curr Opin Psychiatry 2006; 19: 492-496.
12. Guay DR. Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability. Consult Pharm 2007; 22: 1004-1034.
13. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70: 1950-1958.
14. Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol 2007; 11: 331-336.
15. Verrotti A, Manco R, Matricardi S, et al. Antiepileptic drugs and visual function. Pediatr Neurol 2007; 36: 353-360.
16. Huber B, Hauser I, Horstmann V. Long-term course of epilepsy in a large cohort of intellectually disabled patients. Seizure 2007; 16: 35-42.
17. Crawford P, Brown S, Kerr M, et al. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 2001; 10: 107-115.
18. Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 2004; 3: 1-8.
19. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998; 39: 874-877.
20. Alkin T, Onur E, Ozerdem A. Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1339-1340.
21. Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71: 89-101.
22. Kerr MP, Baker GA, Brodie MJ. A randomized, double-blind, placebocontrolled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy Behav 2005; 7: 472-480.
23. Kelly K, Stephen LJ, Sills GJ, et al. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002; 43: 399-402.
24. Chudnow RS, Dewey RB, Lawson CR. Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch Neurol 1997; 54: 910-912.
25. Huber B, Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure 2003; 12: 602-603.
26. Simister RJ, Sander JW, Koepp MJ. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 2007; 10: 336-339.
27. Vendrame M, Khurana DS, Cruz M. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia 2007; 48: 2116-2120.
28. Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004; 62: 640-643.
29. Brodtkorb E, Klees TM, Nakken KO, et al. Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy Behav 2004; 5: 231-235.
30. Dinkelacker V, Dietl T, Widman G, et al. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003; 4: 537-547.
31. Conry JA. Pharmacological treatment of catastrophic epilepsies. Epilepsia 2004; 45(Suppl. 5): 12-16.
32. Landmark CJ. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27-47.
33. Huppke P, Köhler K, Brockmann K, et al. Treatment of epilepsy in Rett syndrome. Eur J Paediatr Neurol 2007; 11: 10-16.
34. Harkin LA, McMahon JM, Iona X, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007; 130: 843-852.
35. Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev 2007; 17: 413-425.
36. Helmstaedter C, Wagner G, Elger CE. Differential effects of first antiepileptic drug application on cognition in lesional and non-lesional patients with epilepsy. Seizure 1993; 2: 125-130.
37. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007; 30: 555-567.
38. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005; 19: 897-908.
39. Szücs A, Clemens Z, Jakus R, et al. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia 2008; 49: 1174-1179.
40. Brown S. Deterioration. Epilepsia 2006; 47(Suppl. 2): 19-23.
41. Deonna T, Roulet E. Autistic spectrum disorder: evaluating a possible or causal role of epilepsy. Epilepsia 2006; 47(Suppl. 2): 79-82.
42. Kim DW, Kim KK, Chu K, et al. Surgical treatment of delayed epilepsy in hemiconvulsion-hemiplegia-epilepsy syndrome. Neurology 2008; 70: 2116-2122.
43. Malmgren K, Olsson I, Engman E, et al. Seizure outcome after resective epilepsy surgery in patients with low IQ. Brain 2008; 131: 535-542.
44. Bjørnaes H, Stabell KE, Heminghyt E, et al. Resective surgery for intractable focal epilepsy in patients with low IQ: predictors for seizure control and outcome with respect to seizures and neuropsychological and psychosocial functioning. Epilepsia 2004; 45: 131-139.
45. Freitag H, Tuxhorn I. Cognitive function in preschool children after epilepsy surgery: rationale for early intervention. Epilepsia 2005; 46: 561-567.
46. You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev 2008; 30: 195-199.
47. Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. Epilepsy Behav 2005; 6: 417-423.
48. Brodtkorb E, Aamo T, Henriksen O, et al. Rectal diazepam: pitfalls of excessive use in refractory epilepsy. Epilepsy Res 1999; 35: 123-133.
49. Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67(Suppl. 4): 39-44.
50. Brodtkorb E, Sand T, Strandjord RE. Neuroleptic and antiepileptic treatment in the mentally retarded. Seizure 1993; 2: 205-211.
51. Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62: 345-354.
52. Brodtkorb E. The diversity of epilepsy in adults with severe developmental disabilities: age at seizure onset and other prognostic factors. Seizure 1994; 3: 277-285.
53. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001; 42: 357-362.
54. McVicker RW, Shanks OE, McClelland RJ. Prevalence and associated features of Down's syndrome. Br J Psychiatr 1994; 164: 528-532.
55. Crespel A, Gonzalez V, Coubes P, Gelisse P. Senile myoclonic epilepsy of Genton: two cases in Down syndrome with dementia and late onset epilepsy. Epilepsy Res 2007; 77: 165-168.
56. Jian L, Nagarajan L, de Klerk N, et al. Seizures in Rett syndrome: an overview from a one-year calendar study. Eur J Paediatr Neurol 2007; 11: 310-317.
57. Pelc K, Boyd SG, Cheron G, et al. Epilepsy in Angelman syndrome. Seizure 2008; 17: 211-217.
58. Incorpora G, Sorge G, Sorge A, Pavone L. Epilepsy in fragile X syndrome. Brain Dev 2002; 24: 766-769.
59. Alvarez N. Discontinuance of antiepileptic medications in patients with developmental disability and diagnosis of epilepsy. Am J Ment Ret 1989; 93: 593-599.
60. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Prognostic index for recurrence of seizures after remission of epilepsy. BMJ 1993; 306: 1374-1378.
61. Specchio LM, Beghi E. Should antiepileptic drugs be withdrawn from seizure free patients? CNS Drugs 2004; 18: 201-212.
62. Delgado MR, Riela AR, Mills J, et al. Discontinuation of antiepileptic drug treatment after two seizure free years in children with cerebral palsy. Pediatrics 1996; 97: 192-197.
63. Zafeiriou DI, Kontopoulos EE, Tsikoulas I. Characteristics and prognosis of epilepsy in children with cerebral palsy. J Child Neurol 1999; 14: 289-294.